This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grill, J. Articles by Kalifa, C. Search for Related Content PubMed PubMed Citation Articles by Grill, J. Articles by Kalifa, C.

Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology

From the Departments of Pediatrics, Biostatistics, Radiology, and Radiotherapy, Institut Gustave Roussy, Villejuif; Department of Neuropathology, University Hospital; Department of Pediatric Hematology/Oncology, La Timone Hospital, Marseille; Department of Pediatric Neurosurgery, Necker Hospital; Department of Pediatrics, Institut Curie, Paris; Department of Pediatrics, Centre Léon Bérard, Lyon; Department of Pediatric Hematology/Oncology, University Hospital, Rennes; and Department of Pediatric Hematology/Oncology, Children’s Hospital, Nancy, France.

Address reprint requests to Chantal Kalifa, MD, Department of Pediatrics, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France; email: kalifa{at}igr.fr

PURPOSE: To evaluate a strategy that avoids radiotherapy in first-line treatment in children under 5 years of age with brain or posterior fossa ependymoma, by exclusively administering 16 months of adjuvant multiagent chemotherapy after surgery.

PATIENTS AND METHODS: Between June 1990 and October 1998, 73 children with ependymoma (82% with high-grade tumors) were enrolled onto this multicenter trial. Children received adjuvant conventional chemotherapy after surgery consisting of seven cycles of three courses alternating two drugs at each course (procarbazine and carboplatin, etoposide and cisplatin, vincristine and cyclophosphamide) over a year and a half. Systematic irradiation was not envisaged at the end of chemotherapy. In the event of relapse or progression, salvage treatment consisted of a second surgical procedure followed by local irradiation with or without second-line chemotherapy.

RESULTS: Conventional chemotherapy was well tolerated and could be administered in outpatient clinics. No radiologically documented response to chemotherapy more than 50% was observed. With a median follow-up of 4.7 years (range, 5 months to 8 years), the 4-year progression-free survival rate in this series was 22% (95% confidence interval [CI], 13% to 43%) and the overall survival rate was 59% (95% CI, 47% to 71%). Overall, 40% (95% CI, 29% to 51%) of the patients were alive having never received radiotherapy 2 years after the initiation of chemotherapy and 23% (95% CI, 14% to 35%) were still alive at 4 years without recourse to this modality. In the multivariate analysis, the two factors associated with a favorable outcome were a supratentorial tumor location (P = .0004) and complete surgery (P = .0009). Overall survival at 4 years was 74% (95% CI, 59% to 86%) for the patients in whom resection was radiologically complete and 35% (95% CI, 18% to 56%) for the patients with incomplete resection.

CONCLUSION: A significant proportion of children with ependymoma can avoid radiotherapy with prolonged adjuvant chemotherapy. Deferring irradiation at the time of relapse did not compromise overall survival of the entire patient population.

This article has been cited by other articles:

				L. Ridley, R. Rahman, M.-A. Brundler, D. Ellison, J. Lowe, K. Robson, E. Prebble, I. Luckett, R. J. Gilbertson, S. Parkes, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma Neuro-oncol, January 1, 2008; 10(5): 675 - 689. [Abstract] [Full Text] [PDF]

				U. Tabori, J. Ma, M. Carter, M. Zielenska, J. Rutka, E. Bouffet, U. Bartels, D. Malkin, and C. Hawkins Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial Ependymoma J. Clin. Oncol., April 1, 2006; 24(10): 1522 - 1528. [Abstract] [Full Text] [PDF]

				T. E. Merchant, R. K. Mulhern, M. J. Krasin, L. E. Kun, T. Williams, C. Li, X. Xiong, R. B. Khan, R. H. Lustig, F. A. Boop, et al. Preliminary Results From a Phase II Trial of Conformal Radiation Therapy and Evaluation of Radiation-Related CNS Effects for Pediatric Patients With Localized Ependymoma J. Clin. Oncol., August 1, 2004; 22(15): 3156 - 3162. [Abstract] [Full Text] [PDF]

				V. Laithier, J. Grill, M.-C. Le Deley, M.-M. Ruchoux, D. Couanet, F. Doz, F. Pichon, H. Rubie, D. Frappaz, J.-P. Vannier, et al. Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy--Results of the First French Prospective Study for the French Society of Pediatric Oncology J. Clin. Oncol., December 15, 2003; 21(24): 4572 - 4578. [Abstract] [Full Text] [PDF]

				S. Dyer, E. Prebble, V. Davison, P. Davies, P. Ramani, D. Ellison, and R. Grundy Genomic Imbalances in Pediatric Intracranial Ependymomas Define Clinically Relevant Groups Am. J. Pathol., December 1, 2002; 161(6): 2133 - 2141. [Abstract] [Full Text] [PDF]

				R. J. Gilbertson, L. Bentley, R. Hernan, T. T. Junttila, A. J. Frank, H. Haapasalo, M. Connelly, C. Wetmore, T. Curran, K. Elenius, et al. ERBB Receptor Signaling Promotes Ependymoma Cell Proliferation and Represents a Potential Novel Therapeutic Target for This Disease Clin. Cancer Res., October 1, 2002; 8(10): 3054 - 3064. [Abstract] [Full Text] [PDF]

				V. Kieffer-Renaux, C. Bulteau, J. Grill, C. Levy-Piebois, D. Couanet, A. Pierre-Kahn, O. Hartmann, and C. Kalifa Visual Agnosia After Treatment of a Posterior Fossa Ependymoma in a 16-Month-Old Girl J Child Neurol, September 1, 2001; 16(9): 698 - 704. [Abstract] [PDF]

				A. C. Paulino, J. M. Buatti, J. Grill, and C. Kalifa Adjuvant Chemotherapy for Ependymoma: Is It Necessary for All Children Under Five Years of Age? J. Clin. Oncol., August 1, 2001; 19(15): 3588 - 3589. [Full Text]